

ROCHE-ASSOCIATED PRESENTATIONS AT EURETINA 2023

THURSDAY, 5 OCTOBER

Roche Symposium Forum 13:30–14:30	FARICIMAB ▼ Change in treatment paradigm for DME with faricimab – Evidence from clinical trials and real-world practice	Tadayoni R, Mitchell P, Sadda S, Holekamp N
Free Paper Presentation Emerald Room 12:19–12:25	FARICIMAB Comparative efficacy of faricimab for the treatment of diabetic macular edema: A systematic literature review and network meta-analysis	Holekamp N, Mar F, Gibson K

FRIDAY, 6 OCTOBER

Roche Symposium E102 09:45–10:45	The future of retinal care to meet the growing demand	Guymer R, Gale R, Moe M, Durand-Zaleski I
Roche Symposium Auditorium 13:45–14:45	FARICIMAB Change in treatment paradigm for nAMD with faricimab – Evidence from clinical trials and real-world practice	Holz F, Mohamed M, Cheung CMG, Khanani A
Roche Symposium E103/104 17:45–18:45	PDS The future of continuous drug delivery for retinal diseases	Graff J, Hillier R, Brittain C, Dolz Marco R
Free Paper Presentation E102 09:07–09:13	PHC The relevance of clinical and imaging features in artificial intelligence-based prediction of geographic atrophy progression	Ferrara D, Cluceru J, Slama O
Free Paper Presentation E102 11:07–11:13	PDS Port Delivery System with ranibizumab in diabetic macular edema: Primary analysis results of the Phase 3 Pagoda trial	Graff J, Marcus D, Campochiaro P
Free Paper Presentation E102 11:13–11:19	FARICIMAB FARETINA-DME six-month treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: An IRIS Registry™ analysis	Bailey C, Tabano D, Borkar D
Free Paper Presentation E102 11:19–11:25	FARICIMAB Automated segmentation of hyperreflective foci in DME shows greater volume reduction in eyes treated with faricimab compared to aflibercept in the Phase 3 YOSEMITE and RHINE clinical trials ¹	Chakravarthy U, Maunz A, Von Schulthess E
Free Paper Presentation Grand Auditorium 12:18–12:23	FARICIMAB The potential for Q20W dosing with faricimab and extended treatment outcomes in neovascular age-related macular degeneration: A post hoc analysis of the pivotal TENAYA/LUCERNE trials	Ambresin A, Koh A, Singer M
Free Paper Presentation E102 13:03–13:09	PDS Optimization of the Port Delivery System with ranibizumab (PDS) implant insertion procedure: Key steps and impact on patient outcomes	Hillier R, Vicente A, Jaycock P
Free Paper Presentation E102 15:46–15:52	FARICIMAB Faricimab personalised treat-and-extend-based dosing dynamics in patients with DME	Figuroa M, Pearce I, Lim J

SATURDAY, 7 OCTOBER

Roche Symposium E103/104 10:15–11:15	FARICIMAB Discovering chANGe with Ang-2	Schlottmann P, Grimaldi G, Khanani A
Free Paper Presentation E102 09:19–09:25	FARICIMAB Faster time to retinal fluid control with faricimab vs aflibercept in patients with DME in the Phase 3 YOSEMITE/RHINE trials ²	Lanzetta P, Rachitskaya A, Camino A
Free Paper Presentation E102 09:25–09:31	FARICIMAB Faricimab reduces macular leakage vs aflibercept in patients with DME ³	Sivaprasad S, Kolomeyer A, Nudleman E
Free Paper Presentation E102 12:19–12:25	Anti-IL-6 A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): Preliminary results from the Phase 1 DOVETAIL study	Pavesio C, Sharma S, Suhler E
Free Paper presentation Speaker's corner 12:36–12:41	FARICIMAB Early treatment patterns of faricimab among neovascular age-related macular degeneration (nAMD) patients in the UK	Talks J, De Salvo G, Patel P
Free Paper Presentation E103/104 15:30–15:36	PDS Pharmacokinetic profile of the Port Delivery System with ranibizumab in the Phase 3 Pagoda trial of diabetic macular edema and the Phase 3 Pavilion trial of diabetic retinopathy without center-involved diabetic macular edema	Dhoot D, Ding HT, Hyung S
Free Paper Presentation E103/104 15:43–15:49	FARICIMAB Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): 1-year results from China subpopulation of Phase 3 RHINE trial	Li X, Sun X, Jiang Q

VIRTUAL

Audio Narrated Free Paper Presentation	FARICIMAB Baseline characteristics and 3-month data from patients receiving faricimab or PDS for nAMD or DME in the real-world VOYAGER study	Sheth V, Bailey C, Bengus M
Audio Narrated Free Paper Presentation	FARICIMAB UK Faricimab Real-World Evidence (FARWIDE) study: Early treatment patterns of faricimab among DME patients in the UK	Bailey C, Peto T, Downey L
Audio Narrated Free Paper Presentation	FARICIMAB Faricimab rapidly improves fluid parameters in patients with nAMD ⁴	Gale R, London N, Kotecha A
Audio Narrated Free Paper Presentation	FARICIMAB Efficacy, durability, and safety of faricimab in neovascular age-related macular degeneration (nAMD): 48-week results from the China subpopulation of the Phase 3 LUCERNE trial	Chen Y, Kotecha A, Willis J
Audio Narrated Free Paper Presentation	FARICIMAB An assessment of the impact of disease activity criteria on dosing interval assignment in clinical trial patients with nAMD	Gallego-Pinazo R, Weng C, Souverain A
Audio Narrated Free Paper Presentation	FARICIMAB Changes in intraocular Ang-2 and VEGF-A following faricimab treatment in nAMD and DME	Cheung G, Bogman K, Diack C
Audio Narrated Free Paper Presentation	FARICIMAB Fibrosis characterisation and prevention in nAMD: Identification of subretinal triggers, cell-types responsible and inhibitors using improved tools	Westenskow P, Ozaki E, Doyle S
Audio Narrated Free Paper Presentation	FARICIMAB Investigating the burden of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) treatment on recipients and caregivers in North America and Europe	Gale R, Tabano D, Cox O
Audio Narrated Free Paper Presentation	FARICIMAB Personalised faricimab dosing increased the proportion of patients with nAMD achieving Q16W dosing in year 2 of TENAYA/LUCERNE, while maintaining functional and anatomical outcomes ⁵	Ambresin A, Kotecha A, Willis J
Audio Narrated Free Paper Presentation	PDS Port Delivery System with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema: Primary analysis results of the Phase 3 Pavilion trial	Wykoff C, Chang M, Emanuelli A
Audio Narrated Free Paper Presentation	PDS Postoperative monitoring and long-term follow-up: A PDS-treated patient case from the Ladder Phase 2 trial continuing into the Portal extension trial	Graff J, Heinrich D, Blotner S
Audio Narrated Free Paper Presentation	PDS Refill-exchange procedure for the Port Delivery System with ranibizumab: Optimization and enhanced training	Becker M, Colina J, Graff J
Audio Narrated Free Paper Presentation	PHC Deep learning segmentation of foveal avascular zone in optical coherence tomography angiography of non-proliferative diabetic retinopathy	Benmansour F, Camino A, Wang Z
Audio Narrated Free Paper Presentation	PHC Visual loss in geographic atrophy: A comprehensive exploratory analysis of function and morphology from the lampalizumab trial programme	Ferrara D, Chakravarthy U, Anagondi N
Audio Narrated Free Paper Presentation	PHC Burden in the clinical management of diabetic macular oedema: A multicentre analysis in the United Kingdom	Peto T, Chen X, Talks J

A new Ophthalmology Network is in sight. Watch this space.

To find out more, meet us at the Roche medical booth!

Please note that timings are subject to change by the EURETINA congress organisers. Please check the official programme for confirmation of timings.

Ang, angiopoietin; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; PDS, Port Delivery System with ranibizumab; PHC, personalised healthcare; QxW, every x weeks; VEGF, vascular endothelial growth factor
1. Maunz A, et al. Invest Ophthalmol Vis Sci. 2023;64:PO039; 2. Pollreiz A, et al. Invest Ophthalmol Vis Sci. 2023;64:2817; 3. Goldberg RA, et al. Invest Ophthalmol Vis Sci. 2023;64:2816; 4. Querques G, et al. Invest Ophthalmol Vis Sci. 2023;24:2185; 5. Chaudhary V, et al. Invest Ophthalmol Vis Sci. 2023;64:5056

This medical-scientific material contains information on therapies³ that may have not yet been approved for use in your country, including by the European Medicines Agency, and for which no adequate statement on safety and efficacy can be made. This information does not intend to promote the use of products prior to or outside the respective marketing authorisation under drug law

⁴Faricimab is approved for the treatment of nAMD and DME in several countries worldwide, including by the European Medicines Agency. Approval conditions may vary internationally. Status as of September 2023. The full SmPC is available at the booth

▼ This medicinal product is subject to additional monitoring

⁵The Port Delivery System with ranibizumab (PDS) is approved for the treatment of nAMD in the US. Status as of September 2023. In October 2022, Roche voluntarily recalled the PDS ocular implant and insertion tool assembly, including the ranibizumab drug vial and initial fill needle, which are sold together in the US, and paused implantations including in ongoing global clinical trials. Roche is committed to bringing the innovation of PDS to patients with retinal diseases and is actively solving the device quality issue

Health care professionals are asked to report any suspected adverse reactions, and may do so via the medinfo.roche.com website